Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

ACES_ Nov. 13 at 7:04 PM

$RCUS loading time

0 · Reply

TheGunnerAB Nov. 13 at 2:28 AM

$RCUS Gilead didn't buy a single share in this offering. The company had 90M shares to start the year. Now 122M. Crazy dilution. Gilead ownership dropped from 31% to 25%

1 · Reply

Randy2979 Nov. 12 at 10:08 PM

$RCUS

0 · Reply

stcks Nov. 12 at 9:51 PM

$RCUS I am not selling. Up 1.5% for last 5 days, 😪 Up 26.5 % for the month, 👍 Up 116.92 % for three months. ❤️ Up 132.56 % for six months. ❤️❤️

0 · Reply

stcks Nov. 12 at 8:49 PM

$RCUS just buy and hold!

1 · Reply

MRTunity Nov. 11 at 9:55 PM

$SLS $VKTX $AUPH $RCUS Been spending more time posting my Technical Analysis & Alerts 🚨 on X- anyone else on X let me know so I can follow ya 👊🏼 https://x.com/tradethetrendta?s=21

2 · Reply

ACES_ Nov. 11 at 11:01 AM

$RCUS bet is placed... may place more chips on the table if this dips again...

0 · Reply

Bobes Nov. 9 at 1:56 PM

$RCUS tigit p3 data coming in 2026. We dont know when but if that hits expect this to be over 50. With both Cas and Tigit in p3 this could be a goldmine. Now the risk is tigit fails but p2 looked really good. The n on p2 was 41 the n on p3 is over 1000. The risk is the larger trial doesnt follow p2 however confidence on p2 was 95%. So place your bets.

1 · Reply

ACES_ Nov. 7 at 4:29 PM

$RCUS yep.. bought more. fuck them

1 · Reply

ACES_ Nov. 7 at 2:43 PM

$RCUS almost time to buy more.......

0 · Reply

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Oct 30, 2025, 4:01 PM EDT - 15 days ago

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Oct 28, 2025, 4:05 PM EDT - 17 days ago

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Oct 19, 2025, 7:00 PM EDT - 26 days ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Oct 16, 2025, 11:18 AM EDT - 4 weeks ago

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets

Oct 12, 2025, 6:05 PM EDT - 4 weeks ago

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Oct 9, 2025, 4:35 PM EDT - 5 weeks ago

Arcus Biosciences Announces New Employment Inducement Grants

Oct 6, 2025, 11:15 PM EDT - 5 weeks ago

Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript

Oct 6, 2025, 2:23 PM EDT - 5 weeks ago

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Oct 6, 2025, 8:00 AM EDT - 5 weeks ago

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Sep 10, 2025, 11:59 AM EDT - 2 months ago

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 5:08 PM EDT - 2 months ago

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Aug 20, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 14, 2025, 8:07 AM EDT - 3 months ago

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

UEC

Aug 10, 2025, 9:34 AM EDT - 3 months ago

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Jul 10, 2025, 8:30 AM EDT - 4 months ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 1, 2025, 10:45 AM EDT - 5 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 6 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 6 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 7 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 8 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 26, 2025, 4:35 PM EST - 9 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 9 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 9 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 9 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 9 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 9 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 10 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 10 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 10 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 11 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 1 year ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 1 year ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

ACES_ Nov. 13 at 7:04 PM

$RCUS loading time

0 · Reply

TheGunnerAB Nov. 13 at 2:28 AM

$RCUS Gilead didn't buy a single share in this offering. The company had 90M shares to start the year. Now 122M. Crazy dilution. Gilead ownership dropped from 31% to 25%

1 · Reply

Randy2979 Nov. 12 at 10:08 PM

$RCUS

0 · Reply

stcks Nov. 12 at 9:51 PM

$RCUS I am not selling. Up 1.5% for last 5 days, 😪 Up 26.5 % for the month, 👍 Up 116.92 % for three months. ❤️ Up 132.56 % for six months. ❤️❤️

0 · Reply

stcks Nov. 12 at 8:49 PM

$RCUS just buy and hold!

1 · Reply

MRTunity Nov. 11 at 9:55 PM

$SLS $VKTX $AUPH $RCUS Been spending more time posting my Technical Analysis & Alerts 🚨 on X- anyone else on X let me know so I can follow ya 👊🏼 https://x.com/tradethetrendta?s=21

2 · Reply

ACES_ Nov. 11 at 11:01 AM

$RCUS bet is placed... may place more chips on the table if this dips again...

0 · Reply

Bobes Nov. 9 at 1:56 PM

1 · Reply

ACES_ Nov. 7 at 4:29 PM

$RCUS yep.. bought more. fuck them

1 · Reply

ACES_ Nov. 7 at 2:43 PM

$RCUS almost time to buy more.......

0 · Reply

Bobes Nov. 6 at 12:12 PM

$RCUS very perplexed on what is happening here. Gild didnt buy but this was not a retail offering since they closed it in 48 hrs and if you look at the vol they didnt dump these on the open market. What made Terry randomly drop er and then do this offering. Not likely to be bad news since he needs to disclose that. So something has to be up. What is it?

0 · Reply

ACES_ Nov. 6 at 8:52 AM

$RCUS so who bought the offering ???

2 · Reply

Randy2979 Nov. 6 at 3:04 AM

$RCUS Did Gilead buy 1.36M shares of the new offering based on this filing? https://d18rn0p25nwr6d.cloudfront.net/CIK-0000882095/dcc17ba4-b7df-4de2-8382-a2ade242f5d8.pdf

1 · Reply

MRTunity Nov. 5 at 4:01 PM

$RCUS @RainMan_17 what was your strategy with RCUS here? What changed?! You do know many times the insiders do these kind of offerings cause greedy faks and want to ensure they themselves feel making enough dough 💰 prior to any formal handshake 🤝 If you truly believed the stock is worth $30+ on drug pipeline and will get at least $30 BO price , why sweat over a couple dollars swing? My avg in this is about $9-$10 when I combine TFSA AND SDRSP ! So drop from $22 I never imagined it would hit organically this quickly to $19 doesn’t faze me one bit! Screen shot of TAX FREE AC as receipt so see I’m not talking shit - my $10 Dec calls up a hell of a lot more

0 · Reply

RainMan_17 Nov. 5 at 2:48 PM

$RCUS I was hoping I was wrong about this stock, but it looks like I was right. The pump post offering didn’t make much sense . This stock needs to stabilize, before it’s safe to reenter imo.

1 · Reply

MRTunity Nov. 4 at 11:58 PM

$RCUS 658K volume in AH?! 👀 am I seeing that right ?

0 · Reply

RunningWithTheBullsLA Nov. 4 at 5:03 PM

$RCUS let’s close above 20.50!!!

1 · Reply

Randy2979 Nov. 4 at 1:48 AM

$RCUS Arcus entered into an underwriting agreement with Leerink Partners LLC and Goldman Sachs & Co. LLC as representatives. The offering: 13,700,000 shares at $18.25/share plus an option for additional 2,055,000 shares exercisable for 30 days. The option was exercised in full: aggregate 15,755,000 shares issued. Net proceeds to Arcus: approximately $269.7 million after discounts and expenses. The agreement contains the standard underwriting, representation, warranties. Importantly: It does not list named institutional investors or strategic partner buyers in the visible portion of the document. https://d18rn0p25nwr6d.cloudfront.net/CIK-0001724521/612afac1-eb44-44c2-a380-8a5a27b61844.pdf

0 · Reply

bryantboy99 Nov. 3 at 8:56 PM

$RCUS wait i thought this was supposed to crash on the offering news?

2 · Reply

MRTunity Nov. 3 at 8:34 PM

$RCUS cmon this time let’s break and not look back!!! LFG 💪 LETS CLOSE ABOVE $20.25+!

0 · Reply

MRTunity Nov. 3 at 8:06 PM

$RCUS $20.20 seems to be the RES! MM or whomever seems to cap the run everytime we get to $20.20 ⚠️ ‼️

0 · Reply

RunningWithTheBullsLA Nov. 3 at 6:19 PM

$RCUS come on baby let’s close over 20!!!

1 · Reply

Market Cap	2.14B
Revenue (ttm)	258.00M
Net Income (ttm)	-283.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.69%
Debt to Equity Ratio	0.22

Volume	924,800
Avg Vol	1,378,844
Day's Range	N/A - N/A
Shares Out	107.97M
Stochastic %K	62%
Beta	0.90
Analysts	Strong Sell
Price Target	$32.36